154 related articles for article (PubMed ID: 27480274)
21. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.
Kiechl S; Schramek D; Widschwendter M; Fourkala EO; Zaikin A; Jones A; Jaeger B; Rack B; Janni W; Scholz C; Willeit J; Weger S; Mayr A; Teschendorff A; Rosenthal A; Fraser L; Philpott S; Dubeau L; Keshtgar M; Roylance R; Jacobs IJ; Menon U; Schett G; Penninger JM
Oncotarget; 2017 Jan; 8(3):3811-3825. PubMed ID: 28002811
[TBL] [Abstract][Full Text] [Related]
22. Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice.
Gil EY; Jo UH; Lee HJ; Kang J; Seo JH; Lee ES; Kim YH; Kim I; Phan-Lai V; Disis ML; Park KH
Breast Cancer Res Treat; 2014 Aug; 147(1):69-80. PubMed ID: 25104444
[TBL] [Abstract][Full Text] [Related]
23. Role of the RANK/RANKL pathway in breast cancer.
Kiesel L; Kohl A
Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
[TBL] [Abstract][Full Text] [Related]
24. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
Vidula N; Yau C; Li J; Esserman LJ; Rugo HS
Breast Cancer Res Treat; 2017 Aug; 165(1):129-138. PubMed ID: 28577080
[TBL] [Abstract][Full Text] [Related]
25. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis.
Schramek D; Sigl V; Penninger JM
Trends Endocrinol Metab; 2011 May; 22(5):188-94. PubMed ID: 21470874
[TBL] [Abstract][Full Text] [Related]
26. RANK as a therapeutic target in cancer.
González-Suárez E; Sanz-Moreno A
FEBS J; 2016 Jun; 283(11):2018-33. PubMed ID: 26749530
[TBL] [Abstract][Full Text] [Related]
27. RANKL/RANK - from bone physiology to breast cancer.
Sigl V; Penninger JM
Cytokine Growth Factor Rev; 2014 Apr; 25(2):205-14. PubMed ID: 24486161
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
29. MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.
Christenson JL; Butterfield KT; Spoelstra NS; Norris JD; Josan JS; Pollock JA; McDonnell DP; Katzenellenbogen BS; Katzenellenbogen JA; Richer JK
Horm Cancer; 2017 Apr; 8(2):69-77. PubMed ID: 28194662
[TBL] [Abstract][Full Text] [Related]
30. Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis.
Pellegrini P; Cordero A; Gallego MI; Dougall WC; Muñoz P; Pujana MA; Gonzalez-Suarez E
Stem Cells; 2013 Sep; 31(9):1954-65. PubMed ID: 23766243
[TBL] [Abstract][Full Text] [Related]
31. Rankl Impairs Lactogenic Differentiation Through Inhibition of the Prolactin/Stat5 Pathway at Midgestation.
Cordero A; Pellegrini P; Sanz-Moreno A; Trinidad EM; Serra-Musach J; Deshpande C; Dougall WC; Pujana MA; González-Suárez E
Stem Cells; 2016 Apr; 34(4):1027-39. PubMed ID: 26695351
[TBL] [Abstract][Full Text] [Related]
32. Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.
Zheng Y; Chow SO; Boernert K; Basel D; Mikuscheva A; Kim S; Fong-Yee C; Trivedi T; Buttgereit F; Sutherland RL; Dunstan CR; Zhou H; Seibel MJ
J Bone Miner Res; 2014 Sep; 29(9):1938-49. PubMed ID: 24676805
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of the Kit ligand/c-Kit axis attenuates metastasis in a mouse model mimicking local breast cancer relapse after radiotherapy.
Kuonen F; Laurent J; Secondini C; Lorusso G; Stehle JC; Rausch T; Faes-Van't Hull E; Bieler G; Alghisi GC; Schwendener R; Andrejevic-Blant S; Mirimanoff RO; Rüegg C
Clin Cancer Res; 2012 Aug; 18(16):4365-74. PubMed ID: 22711708
[TBL] [Abstract][Full Text] [Related]
34. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
35. Multifunctional properties of RANKL/RANK in cell differentiation, proliferation and metastasis.
Kukita A; Kukita T
Future Oncol; 2013 Nov; 9(11):1609-22. PubMed ID: 24156322
[TBL] [Abstract][Full Text] [Related]
36. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
Li Y; Kucuk O; Hussain M; Abrams J; Cher ML; Sarkar FH
Cancer Res; 2006 May; 66(9):4816-25. PubMed ID: 16651437
[TBL] [Abstract][Full Text] [Related]
37. Dominant negative N-cadherin inhibits osteoclast differentiation by interfering with beta-catenin regulation of RANKL, independent of cell-cell adhesion.
Shin CS; Her SJ; Kim JA; Kim DH; Kim SW; Kim SY; Kim HS; Park KH; Kim JG; Kitazawa R; Cheng SL; Civitelli R
J Bone Miner Res; 2005 Dec; 20(12):2200-12. PubMed ID: 16294273
[TBL] [Abstract][Full Text] [Related]
38. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
[TBL] [Abstract][Full Text] [Related]
39. RANK expression as a prognostic and predictive marker in breast cancer.
Pfitzner BM; Branstetter D; Loibl S; Denkert C; Lederer B; Schmitt WD; Dombrowski F; Werner M; Rüdiger T; Dougall WC; von Minckwitz G
Breast Cancer Res Treat; 2014 Jun; 145(2):307-15. PubMed ID: 24737168
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
Bai YD; Yang FS; Xuan K; Bai YX; Wu BL
Med Hypotheses; 2008 Aug; 71(2):256-8. PubMed ID: 18445511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
